Bristol Myers Squibb – Fourth Quarter – Full-Year Results – 2021

Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021

Reports Fourth Quarter Revenues of $12.0 Billion; Full-Year Revenues of $46.4 Billion

Posts Fourth Quarter Earnings Per Share of $1.07 and Non-GAAP EPS of $1.83; Posts Full-Year Earnings Per Share of $3.12 and Non-GAAP EPS of $7.51

Delivers Strong Revenues for Eliquis, Immuno-Oncology, and New Product Portfolios

Advances Pipeline with Achievement of Significant Clinical and Regulatory Milestones; Builds Strong Foundation for Portfolio Renewal

Announces $15 Billion Share Repurchase Authorization; $5 Billion Accelerated Share Repurchase Agreement to be Executed During the First Quarter 2022

Provides GAAP and More Detailed Non-GAAP Financial Guidance for 2022

Reaffirms Long-term Financial Targets

NEW YORK (STL.News) Bristol Myers Squibb (NYSE: BMY) today reports results for the fourth quarter and full year of 2021, which reflect strong sales driven by robust commercial execution and significant advancement of the company’s pipeline that further progressed the company’s portfolio renewal.

“I am proud of how our company performed in 2021, helping more patients across our therapeutic areas while achieving 9% revenue and 17% non-GAAP EPS growth, respectively,” said Giovanni Caforio, M.D., board chair and chief executive officer, Bristol Myers Squibb.  “2021 was a pivotal year for our company as we achieved significant regulatory and clinical milestones and positioned the company to successfully renew our portfolio.  I am confident in our ability to execute against our key milestones in 2022, including three planned first-in-class launches with relatlimab plus nivolumab fixed-dose combination, mavacamten, and deucravacitinib.  Our financial strength, dedicated workforce, and proven ability to execute will enable us to continue to advance our pipeline, invest in future sources of innovation, and position the company for sustained growth.”

NOTE: This is NOT the complete release.  Visit the Bristol Myers website for complete details.

SOURCE: Bristol Myers